Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation
-
Published:2021-04
Issue:
Volume:27
Page:100351
-
ISSN:2212-1374
-
Container-title:Journal of Bone Oncology
-
language:en
-
Short-container-title:Journal of Bone Oncology
Author:
McGee Sharon,
AlZahrani Mashari,
Stober Carol,
Ng Terry L.ORCID,
Cole KatherineORCID,
Larocque GailORCID,
Awan ArifORCID,
Sehdev Sandeep,
Hilton John,
Vandermeer Lisa,
Hutton Brian,
Pond Gregory,
Saunders Deanna,
Clemons MarkORCID
Reference39 articles.
1. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials;Early Breast Cancer Trialists' Collaborative Group;Lancet,2015
2. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline;Dhesy-Thind;J. Clin. Oncol.,2017
3. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG;Hadji;J. Bone Oncol,2017
4. Bone health in cancer: ESMO clinical practice guidelines;Coleman;Ann. Oncol.,2020
5. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial;Coleman;Lancet Oncol.,2014
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献